Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors
Stopped early · Phase 1
Conditions studied: Solid Tumor, Microsatellite Stable Colorectal Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Cervical Cancer, Melanoma (Skin), Cutaneous Squamous Cell Carcinoma, Mesothelioma, Renal Cell Carcinoma, Oropharynx Cancer
In brief
To determine the recommended Phase 2 dose (RP2D) of TBio-6517 when administered by direct injection into tumor(s) or intravenously and when combined with pembrolizumab in patients with solid tumors (RIVAL-01).
Key facts
- Study ID
- NCT04301011
- Run by
- Turnstone Biologics, Corp.
- People needed
- 27
- Starts
- 2020-06-02
- Expected to finish
- 2023-01-23
- Last updated by the study team
- 2025-04-23
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Mayo Clinic — Phoenix, Arizona, United States
- Mayo Clinic — Jacksonville, Florida, United States
- Sylvester Comprehensive Cancer Center / UMHC — Miami, Florida, United States
- University of Kansas Medical Center — Kansas City, Kansas, United States
- Clinical Site 1007 — Boston, Massachusetts, United States
- Mayo Clinic — Rochester, Minnesota, United States
- The Billings Clinic — Billings, Montana, United States
- University of Texas MD Anderson Cancer Center — Houston, Texas, United States
- Ottawa Hospital and Research Institute (OHRI) — Ottawa, Ontario, Canada
- National Cancer Center — Ilsandong, South Korea
- Seoul National University Hospital (SNUH) — Junggu, South Korea
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.